NaPro Selling Paclitaxel Line To Faulding To Focus On New Cancer Agents
Executive Summary
NaPro is trading its generic paclitaxel business for $50 mil. in cash to invest in new cancer agents and projects based on its "gene editing" technology
You may also be interested in...
NaPro/Abbott Paclitaxel Licenses Settle Patent Dispute, Create “Tripwires”
NaPro Biotherapeutics' annual paclitaxel capacity will reach 100 kg by the time of the expected U.S. launch in early 2002, CEO Leonard Shaykin said Nov. 30
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials